Format

Send to

Choose Destination
Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Collaborators (175)

Jäger G, Jäger U, Ruckser R, Thaler J, Bell R, Cannell P, Cartwright K, Enno A, Fay K, Filshie R, Gibson J, Gill D, Green M, Grigg A, Hertzberg MS, Horvath N, Irving I, Kanourakis G, Leahy M, Lowenthal R, Ma D, Norman E, Prosser W, Schwarer A, Smith CL, Tileay CR, Underhill C, Wolf M, Alves de Souza Scheliga A, Belch A, Bence-Bruckler I, Burnell M, Cantin G, Charpentier D, Crump M, Desjardins P, Findlay B, Gapski J, Howson-Jan K, Imrie K, Matthews J, Pressnail B, Sheperd L, Stevens R, Stewart D, Tompkins K, Voralia M, White D, Bolomská I, Jankovská M, Kubáckova K, Matuska M, Papajík T, Pytlík R, Siffnerová H, Trneny M, Vásová I, Vozobulová V, Zák P, Boesen AM, de Nully Brown P, Hansen M, Plesner T, Lehtinen T, Pyrhönen S, Teerenhovi L, Colombat P, Maisonneuve H, Milpied N, Andreesen R, Aulitzky W, Berdel W, Bodenstein H, Brugger W, Clemens M, deWit M, Döhner H, Dörken B, Eimermacher H, Franke A, Frickhofen N, Haas R, Herold M, Hiddemann W, Ho A, Höffken K, Hoelzer D, Huber C, Kneba M, Mergenthaler HG, Metzner B, Mantovani L, Nerl C, Peest D, Pfreundschuh M, Pielken HJ, Reiser M, Schlimok G, Schmitz N, Trümper L, Steinhauer HB, Uppenkamp M, Verbeek W, Berrebi A, Cohen A, Kornberg A, Raanani P, Rachmilevitz E, Shpilberg O, Yehuda B, Yukla M, Amadori S, Falini B, Fanin R, Foa R, Gobbi M, Mazza P, Zaccaria A, Zinzani PL, Ekanger R, Johnsen H, Kvaløy S, Maisenhølder M, Östenstad B, Telhaug R, Dmoszyńska A, Hellmann A, Hołowiecki J, Jedrzejczak W, Robak T, Sułek K, Utracka-Hutka B, Walewski J, Caballero Barrigón D, Conde García E, Díaz Mediavilla J, Guillermo AL, Adriansson M, Andreassen L, Cavallin-Ståhl E, Erlanson M, Fredén S, Hagberg H, Hedenus M, Johansson JE, Kimby E, Lauri B, Lindblom A, Österborg A, Rådlund A, Rylander H, Betticher D, Ghielmini M, Hitz F, Mingrone W, Pless M, Stahel R, Widmer LA, Cunningham D, Dyer JS, Evely R, Hancock B, Hatton C, Haynes A, Hoskin P, Johnson P, Lister A, Marcus R, Milligan DW, Morris TC, Pettengell R, Pettitt A, Poynton C, Tighe J, Wimperis J.

Author information

1
Universitätsklinikum des Saarlandes, Homburg, Germany. michael.pfreundschuh@uks.eu

Abstract

BACKGROUND:

The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen in young patients with good-prognosis diffuse large-B-cell lymphoma. Extended follow-up was needed to establish long-term effects.

METHODS:

In the randomised open-label MInT study, patients from 18 countries (aged 18-60 years with none or one risk factor according to the age-adjusted International Prognostic Index [IPI], stage II-IV disease or stage I disease with bulk) were randomly assigned to receive six cycles of a CHOP-like chemotherapy with or without rituximab. Bulky and extranodal sites received additional radiotherapy. Randomisation was done centrally with a computer-based tool and was stratified by centre, bulky disease, age-adjusted IPI, and chemotherapy regimen by use of a modified minimisation algorithm that incorporated a stochastic component. Patients and investigators were not masked to treatment allocation. The primary endpoint was event-free survival. Analyses were by intention to treat. This observational study is a follow-up of the MInT trial, which was stopped in 2003, and is registered at ClinicalTrials.gov, number NCT00400907.

FINDINGS:

The intention-to-treat population included 410 patients assigned to chemotherapy alone and 413 assigned to chemotherapy plus rituximab. After a median follow-up of 72 months (range 0·03-119), 6-year event-free survival was 55·8% (95% CI 50·4-60·9; 166 events) for patients assigned to chemotherapy alone and 74·3% (69·3-78·6; 98 events) for those assigned to chemotherapy plus rituximab (difference between groups 18·5%, 11·5-25·4, log-rank p<0·0001). Multivariable analyses showed that event-free survival was affected by treatment group, presence of bulky disease, and age-adjusted IPI and that overall survival was affected by treatment group and presence of bulky disease only. After chemotherapy and rituximab, a favourable subgroup (IPI=0, no bulk) could be defined from a less favourable subgroup (IPI=1 or bulk, or both; event-free survival 84·3% [95% CI 74·2-90·7] vs 71·0% [65·1-76·1], log-rank p=0·005). 18 (4·4%, 95% CI 2·6-6·9) second malignancies occurred in the chemotherapy-alone group and 16 (3·9%, 2·2-6·2) in the chemotherapy and rituximab group (Fisher's exact p=0·730).

INTERPRETATION:

Rituximab added to six cycles of CHOP-like chemotherapy improved long-term outcomes for young patients with good-prognosis diffuse large-B-cell lymphoma. The definition of two prognostic subgroups allows a more refined therapeutic approach to these patients than does assessment by IPI alone.

FUNDING:

Hoffmann-La Roche.

Comment in

PMID:
21940214
DOI:
10.1016/S1470-2045(11)70235-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center